Chinook Therapeutics, Inc. (KDNY) Social Stream



Chinook Therapeutics, Inc. (KDNY): $13.85

1.26 (+10.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KDNY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Chinook Therapeutics Inc (KDNY) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering KDNY.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 7 $40 $25 $33.166 $16.74 98.12%
2021-11-15 7 $40 $25 $33 $16.74 97.13%
2022-01-26 6 $40 $25 $31.166 $16.74 86.18%
2022-03-22 6 $40 $25 $31.333 $16.74 87.17%

The Trend in the Analyst Price Target


Over the past 28 weeks, KDNY's average price target has gone down $1.38.

Over the past 48 weeks, KDNY's average upside potential has been 115.69%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-21 7 40 25 31.710 14.89 112.96%
2021-07-10 7 40 25 31.570 14.79 113.46%
2021-11-08 7 40 25 33.166 14.19 133.73%
2021-11-12 7 40 25 33.000 16.46 100.49%
2021-11-15 7 40 25 33.000 16.22 103.45%

KDNY Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The Trend in the Broker Recommendations


Over the past 120 days, KDNY's average broker recommendation rating improved by 0.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for KDNY as an investment opportunity.

  • In the context of all US stocks, Chinook Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 380.87% of them.
  • To contextualize these metrics, consider that out of all US stocks, Chinook Therapeutics Inc's average analyst price target is higher than 188.14% of them.
  • Chinook Therapeutics Inc's variance in analysts' estimates is lower than -210.79% of all US stocks.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, Chinook Therapeutics Inc's number of analysts covering the stock is higher than 212.41% of them.

In the Pharmaceutical Products industry, ITCI, ISEE, and IRWD are the three stocks most similar to Chinook Therapeutics Inc regarding the price target and analyst recommendation information presented here.

Is KDNY a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5615 seconds.